Anti-Amyloid Alzheimer's Drugs: Who Qualifies and What the 2026 Evidence Shows

For the first time, drugs exist that change the course of early Alzheimer's rather than only easing symptoms. Lecanemab (Leqembi) and donanemab (Kisunla) clear amyloid plaque and modestly slow decline. In 2026 they are more accessible than at launch, but the trade-offs are real.

Key Takeaways

• Leqembi (2023) and Kisunla (2024) are FDA-approved anti-amyloid antibodies for early Alzheimer's, mild cognitive impairment or mild dementia with confirmed amyloid (FDA, 2023 to 2024).
• They slow decline by roughly a quarter to a third over about 18 months in trials, not a cure or reversal (phase 3 trials, 2022 to 2024).
• The key risk is ARIA, brain swelling or microbleeds seen on MRI, which is why regular scans and ApoE genetic testing are part of the plan.
• Medicare covers both for eligible patients, and a 2026 at-home lecanemab injector eased the logistics, but MRI monitoring remains mandatory.

Who Actually Qualifies?

Both drugs are approved only for early disease: mild cognitive impairment or mild dementia due to Alzheimer's, with confirmed amyloid pathology (FDA prescribing information, 2023 to 2024). Confirmation comes from PET imaging, spinal fluid, or increasingly a blood biomarker. Moderate or advanced dementia was not studied and is not an indication.

This narrow window is the most common reason people do not qualify. Our women's longevity 2026 guide frames prevention as the broader goal, since these drugs help only after pathology is present.

Citation capsule: Lecanemab and donanemab are monoclonal antibodies that bind amyloid beta and clear plaques; in their pivotal trials they slowed clinical decline by about 27 percent and 35 percent respectively over 18 months in early Alzheimer's, while carrying a boxed warning for amyloid-related imaging abnormalities (phase 3 publications, 2022 to 2024; FDA labels).

What Is the Real Benefit?

Honest expectations matter. These drugs slow the rate of decline; they do not restore memory or stop the disease. In trials, treated patients declined more slowly than untreated ones, a difference visible in groups but not as an obvious change in any single person. Families should enter treatment understanding "more time at higher function," not recovery.

The 2026 pipeline is large, with tau-targeting and prevention trials underway, but those are not yet approved options.

What Is the ARIA Risk?

ARIA, amyloid-related imaging abnormalities, means brain swelling or small bleeds detected on MRI. Most are silent, but some cause headache, confusion, or rarely serious events. Guidance calls for baseline MRI and follow-up scans before certain doses, with ApoE4 genetic testing to flag highest-risk patients (FDA drug safety communication, August 2025; updated labels, 2025 to 2026).

That monitoring is the hidden workload: repeated scans, specialist visits, and for some, infusions. A 2026 subcutaneous lecanemab autoinjector reduced infusion-center trips but did not remove the MRI schedule (Eisai, July 2026).

How Does Coverage Work?

Medicare covers both under Part B for eligible patients, typically with 20 percent coinsurance after the deductible, and often requires participation in a data registry (Medicare monoclonal antibody coverage, 2026). Medicaid and private plans vary. The at-home injector may fall under Part D, which in 2026 has an out-of-pocket cap, potentially lowering cost for some.

If coverage stalls, our prescription unaffordable guide has appeal steps.

Frequently Asked Questions

Will it make my parent better?

No. It slows decline modestly; it does not reverse damage or restore memory.

Is the MRI monitoring optional?

No. Regular MRIs are required to catch ARIA early.

Can someone with moderate dementia get it?

Not per the approved indication; the trials studied only early-stage patients.

Does Medicare pay?

Yes, for eligible patients, usually under Part B with coinsurance and registry participation.

Conclusion

Anti-amyloid drugs are a genuine milestone: the first treatments that alter early Alzheimer's trajectory. They are also narrow, monitored, and modest in effect, best understood as a way to buy more quality time under close supervision. Discuss eligibility, ARIA monitoring, and coverage with a dementia specialist before deciding.

Cluster: This article belongs to our healthy aging cluster. Read women's longevity 2026, prescription unaffordable cost-cutting, and pharmacist interaction call.